EASO is pleased to be part of a consortium of 18 partners across the world in announcing TIMESPAN - an innovative approach to management of ADHD using Real-World Data.

TIMESPAN’s main objective is to advance the management of patients with Attention Deficit Hyperactivity Disorders (ADHD), who also suffer from cardiometabolic disease – including obesity – by improving available treatments and risk stratification.

Emerging evidence points at a strong association and shared genetic traits between adult ADHD and cardiometabolic diseases like Obesity, Type-2 Diabetes and cardiovascular disease, which, when inadequately treated can lead to adverse outcomes and substantial costs for society.

Various national guidelines of cardiometabolic disease already stressed the importance of concurrent psychiatric disorders, however knowledge about appropriate management of cardiometabolic disease in ADHD is lacking. This is problematic given that ADHD is a common and serious condition, which affects between 2 and 5 % of adults.

TIMESPAN seeks to address the main objective using existing large-scale cohort studies and linked electronic health record databases in multiple countries with different health care systems. We also make use of smartphones and wearable devices to obtain novel real-time and data rich measurements of ADHD medication treatment and cardiometabolic risks.

The combined use of unparalleled data sources and new technologies for data collection, management and analysis will identify optimized and personalized treatment approaches across multiple disciplines that will minimize harm and maximize positive changes, both in disease prognosis and to improve treatment continuity.

TIMESPAN is expected to improve the clinical outcomes, as well as quality of life in adult ADHD patients with co-occurring cardiometabolic disease first and foremost.

But it will also serve to facilitate developments of new technological tools for advanced data management, monitoring and analytics for European stakeholders.

Finally, TIMESPAN develops dedicated strategies to inform clinicians, patients, health authorities, and the general public, to allow for a sustainable implementation of our findings, like recommendations for treatment guidelines.


TIMESPAN unites a strong, multidisciplinary team of 18 partners from academia, small and medium-sized enterprises (SMEs), patients and care providers, including many research groups with a leading international position in their discipline.

Timespan Project Map

The project’s scientific coordinator, Prof. Dr. Henrik Larsson is Principal Investigator and Coinvestigator for several national and international grants that focus on the causes and consequences of ADHD. Concentris research management gmbh manages the project and communicates its progress to the public.

  1. Aarhus Universitet (AU), Denmark
  2. ADD Information Services (ADDISS), United Kingdom
  3. concentris research management gmbh (concentris), Germany
  4. Empatica SRL (Empatica), Italy
  5. Fundació Hospital Universitari Vall d’Hebron – Institut de Recerca (VHIR), Spain
  6. Háskóli Íslands (UoI), Iceland
  7. Karolinska Institutet (KI), Sweden
  8. King ́s College London (KCL), United Kingdom
  9. Örebro University (ORU), Sweden
  10. SUNY Upstate Medical University (SUNY), United States of America
  11. Tartu Ülikool (UTARTU), Estonia
  12. The European Association for the Study of Obesity (EASO), Ireland
  13. University College London (UCL), United Kingdom
  14. Universitet I Bergen (UiN), Norway
  15. University Medical Center Groningen (UMCG), The Netherlands
  16. University of New South Wales (UNSW), Australia
  17. 17. The University of Hong Kong (HKU), Hong Kong
  18. Tartu Ülikool (UTARTU), Estonia


Prof. Dr. Henrik Larsson
TIMESPAN Coordinator

Dr. Christiana Krammer
Project Manager

Veronika Pičmanová
Dissemination Manager


Learn more about the project via the TIMESPAN website: http://timespan.eu/

Follow the project on:





This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 965381. This press release reflects only the view of the author, and the European Commission is not responsible for any use that may be made of the information it contains. Reproduction is authorized provided the source is acknowledged